专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010151095A1 NOVEL ACETYLSALICYLIC ACID SALTS 审中-公开
标题翻译：新型乙酰胆碱盐
公开(公告)号：WO2010151095A1
公开(公告)日：2010-12-29
申请号：PCT/LV2010/000007
申请日：2010-06-21
申请人： TETRA, SIA , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LABEDEVS, Antons , MISNOVS, Anatolijs
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LABEDEVS, Antons , MISNOVS, Anatolijs
IPC分类号： C07C69/157 , C07C229/12 , C07C229/22 , C07C243/40 , A61K31/205 , A61K31/616 , A61P9/08 , A61P29/00 , A61P7/02
CPC分类号： C07C229/12 , A61K31/616 , C07C69/157 , C07C229/22 , C07C243/40
摘要： Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylate (meldonium acetylsalicylate), Z-carnitine acetylsalicylate and 3- (trimethylammonioamino)-propanoate (meldonium) acetylsalicylate. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.
摘要翻译：乙酰水杨酸的新型甜菜碱盐，即乙酰水杨酸丙磺酸4-三甲基氨基丁酸酯（乙酰水杨酸镁），乙酰水杨酸Z-肉碱和乙酰水杨酸3-（三甲基氨基氨基）丙酸酯（meldonium）。使用乙酰水杨酸米曲坦作为抗血小板药，用于治疗血小板聚集，抗炎和抗高脂血症药物诱导的各种病理。

2. 发明申请

WO2003022263A1 PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-BUTYROBETAINE FOR STIMULATING THE SEXUAL ACTIVITY AND POTENCY 审中-公开
标题翻译：包含GAMMA-BUTYROBETAINE用于刺激性活动和兴奋剂的药物组合物
公开(公告)号：WO2003022263A1
公开(公告)日：2003-03-20
申请号：PCT/LV2002/000005
申请日：2002-03-04
申请人： KALVINSH, Ivars , VEVERIS, Maris , BIRMANS, Anatolijs
发明人： KALVINSH, Ivars , VEVERIS, Maris , BIRMANS, Anatolijs
IPC分类号： A61K31/205
CPC分类号： A61K31/519 , A61K31/205 , A61K2300/00
摘要： New medical use for gamma-butyrobetaine is disclosed. Also disclosed are pharmaceutical compositions, containing gamma-butyrobetaine or combination thereof with L-carnitine or sildenafil for oral, parenteral, subcutaneous, transdermal, topical, sublingual, intrauetral, intranasal or rectal application, useful for stimulation of sexual activity and potency in mammals. The disclosed compositions, when applied orally for 6 weeks to non-narcotized male rats substantially increase their sexual activity, decreasing the arousal time, increasing the number of copulations and resultativeness of mounting attempts. When applied by intracavernous or intravenous route said pharmaceutical compositions increase intracorporeal pressure and duration of erection, as well as restore stimulation-induced reflectory erections in anesthetized animals.
摘要翻译：公开了γ-丁基甜菜碱的新用途。还公开了含有γ-丁基甜菜碱或其与L-肉毒碱或西地那非的组合的药物组合物，用于口服，肠胃外，皮下，经皮，局部，舌下，耳内，鼻内或直肠应用，可用于刺激哺乳动物的性活动和效力。所公开的组合物当向非麻醉的雄性大鼠口服6周时大大增加其性活动，减少觉醒时间，增加交配次数和安装尝试的有效性。当通过海绵体内或静脉内途径施用时，所述药物组合物增加体内压力和勃起持续时间，以及恢复麻醉动物中刺激诱导的反射勃起。

3. 发明申请

WO1997006795A1 PHARMACEUTICAL COMPOSITIONS CONTAINING GAMMA-BUTYROBETAIN FOR TREATMENT OF BLOOD FLOW DISORDERS 审中-公开
标题翻译：用于治疗血液流动性疾病的含有γ-氨基丁酸的药物组合物
公开(公告)号：WO1997006795A1
公开(公告)日：1997-02-27
申请号：PCT/LV1996000003
申请日：1996-08-20
申请人： KALVINSH, Ivars , VEVERIS, Maris
IPC分类号： A61K31/205
CPC分类号： A61K31/205
摘要： The invention relates to gamma -butyrobetaine-containing pharmaceutical compositions for oral, parenteral, subcutaneous or rectal administrations, that are providing for the treatment blood circulation disturbances of various genesis and localisation. This composition in the experiments on anaesthesized cats at a dose of 10 mg/kg, i.v. increases the total blood flow by 12 %, not considerably changing blood pressure and heart rhythm. The composition arrests adrenaline-induced isolated rabbit ear blood-vessel spasms. In a concentration of 2.0 mM it decreases reperfusion pressure by 18 %. NO-synthase blocking reverses the composition effect on adrenaline-caused blood-vessel spasms. Being infused the composition at a dose of 200 mg/kg significantly increases blood coagulation during phases I-II. In the comparative experiments the disclosed composition demonstrates more potent effect compared to known medicine [3-(2,2,2-trimethylhydrazinium)propionate]. The preparation is distinguished by a low toxicity and wide safety margin.
摘要翻译：本发明涉及用于口服，肠胃外，皮下或直肠给药的含有γ-丁酸甜菜碱的药物组合物，其用于治疗各种发生和定位的血液循环障碍。在10mg / kg剂量的麻醉猫的实验中的这种组合物，i.v。总血液流量增加12％，不会显着改变血压和心律。该组合物阻止肾上腺素诱导的分离的兔耳血管痉挛。浓度为2.0 mM时，再灌注压降低18％。 NO合成酶阻断反转对肾上腺素引起的血管痉挛的组合效应。以200mg / kg的剂量输注组合物在I-II期期间显着增加血液凝固。在比较实验中，与已知的药物[3-（2,2,2-三甲基肼）丙酸酯]相比，所公开的组合物显示更强的效果。该制剂的特点是毒性低，安全性较高。

4. 发明申请

WO2010151096A1 THERAPEUTIC COMBINATIONS OF NICOTINIC ACID AND MELDONIUM 审中-公开
标题翻译：尼古丁酸和马铃薯的治疗组合
公开(公告)号：WO2010151096A1
公开(公告)日：2010-12-29
申请号：PCT/LV2010/000008
申请日：2010-06-21
申请人： TETRA, SIA , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
IPC分类号： A61K31/197 , A61K31/366 , A61K31/455 , A61P3/06 , A61P7/02 , A61P9/10
CPC分类号： A61K31/197 , A61K31/366 , A61K31/455 , A61K2300/00
摘要： The present invention comprises a synergistic combination of nicotinic acid and meldonium characterized by increased efficiency in treating disorders, including platelet aggregation, dyslipidemia, hyperlipidemia, atherosclerosis, coronary heart disease as chosen from the group of angina pectoris and myocardial infarction, transient and permanent ischemic attack including cerebrovascular accident and stroke and peripheral arterial occlusive disease, and by reduced flushing effect and/or increase of blood glucose levels, comprising as active ingredients nicotinic acid or pharmaceutically acceptable salt thereof and meldonium or pharmaceutically acceptable salt thereof, effective for said purpose.
摘要翻译：本发明包括烟酸和咪达唑的协同组合，其特征在于治疗疾病（包括血小板聚集，血脂异常，高脂血症，动脉粥样硬化，冠状动脉心脏病，选自心绞痛和心肌梗塞，短暂性和永久性缺血发作包括脑血管意外和中风和外周动脉闭塞性疾病，以及通过减少冲洗效应和/或增加血糖水平，其包含作为有效成分的烟酸或其药学上可接受的盐和米曲唑或其药学上可接受的盐。

5. 发明申请

WO2010149658A2 PHARMACEUTICAL COMPOSITION OF GAMMA-BUTYROBETAINE OR A PHARMACEUTICALLY ACCEPTABLE SALT AND MELDONIUM OR A PHARMACEUTICALLY ACCEPTABLE SALT 审中-公开
标题翻译：氨基丁酸或药物可接受的盐和麦芽糖或药物可接受的盐的药物组合物
公开(公告)号：WO2010149658A2
公开(公告)日：2010-12-29
申请号：PCT/EP2010058824
申请日：2010-06-22
申请人： GRINDEKS JSC , KALVINS IVARS , BIRMANS ANATOLIJS , VEVERIS MARIS , LEBEDEVS ANTONS , MISNOVS ANATOLIJS
发明人： KALVINS IVARS , BIRMANS ANATOLIJS , VEVERIS MARIS , LEBEDEVS ANTONS , MISNOVS ANATOLIJS
IPC分类号： A61K31/197 , A61P9/10 , A61P25/00
CPC分类号： A61K31/197 , A61K2300/00
摘要： Pharmaceutical composition of gamma-butyrobetaine and Meldonium dihydrate and its use in prevention and/or treatment of atherosclerosis and/or neurological diseases.
摘要翻译： γ-丁内酯和米曲坦二水合物的药物组合物及其在预防和/或治疗动脉粥样硬化和/或神经疾病中的用途。

6. 发明申请

WO1997004767A1 HYDROXYL RADICAL SCAVENGER 审中-公开
标题翻译：羟基杀虫剂
公开(公告)号：WO1997004767A1
公开(公告)日：1997-02-13
申请号：PCT/JP1996002057
申请日：1996-07-23
申请人： TAIHO PHARMACEUTICAL CO., LTD. , VALSTS ZINATNISKA IESTADE - BEZPELNAS ORGANIZACIJA , KALVINSH, Ivars , VEVERIS, Maris , ABIKO, Yasushi , TAJIMA, Kiyotaka
发明人： TAIHO PHARMACEUTICAL CO., LTD. , VALSTS ZINATNISKA IESTADE - BEZPELNAS ORGANIZACIJA
IPC分类号： A61K31/205
CPC分类号： A61K31/205
摘要： A hydroxyl radical scavenger which comprises as the active ingredient betaines represented by the following general formula (1) or acid-addition salts or esters thereof: (CH3)3N (CH2)nCOO [n = 1 to 5] and a remedy composition for diseases caused by hydroxy radicals. Because of having an excellent effect of scavenging hydroxyl radicals, this compound is useful in treating diseases, in particular, cardiac diseases caused by hydroxyl radicals.
摘要翻译：作为活性成分的羟基自由基清除剂，其含有下述通式（1）所示的甜菜碱或其酸加成盐或酯：（CH 3）3 N +（CH 2）n COO - [n = 1〜5] 以及由羟基引起的疾病的补救组合物。由于具有清除羟基自由基的优异效果，该化合物可用于治疗疾病，特别是由羟基引起的心脏疾病。

7. 发明申请

WO2010149658A3 PHARMACEUTICAL COMPOSITION COMPRISING GAMMA - BUTYROBETAINE AND MELDONIUM 审中-公开
公开(公告)号：WO2010149658A3
公开(公告)日：2010-12-29
申请号：PCT/EP2010/058824
申请日：2010-06-22
申请人： Grindeks, a joint stock company , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
IPC分类号： A61K31/197 , A61P9/10 , A61P25/00
摘要： Pharmaceutical composition of gamma-butyrobetaine and Meldonium dihydrate and its use in prevention and/or treatment of atherosclerosis and/or neurological diseases.

8. 发明申请

WO2010149654A1 PHARMACEUTICAL COMPOSITION OF GAMMA-BUTYROBETAINE OR A PHARMACEUTICALLY ACCEPTABLE SALT AND MELDONIUM OR A PHARMACEUTICALLY ACCEPTABLE SALT 审中-公开
标题翻译：氨基丁酸或药物可接受的盐和麦芽糖或药物可接受的盐的药物组合物
公开(公告)号：WO2010149654A1
公开(公告)日：2010-12-29
申请号：PCT/EP2010/058818
申请日：2010-06-22
申请人： GRINDEKS, a joint stock company , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
IPC分类号： A61K31/194 , A61K31/197 , A61P3/06 , A61P9/00 , A61P9/04 , A61P9/10
CPC分类号： A61K31/194 , A61K31/197 , A61K2300/00
摘要： Gamma-butyrobetaine succinate and pharmaceutical composition thereof. New pharmaceutical composition relates to prevention and/or treatment of a disorder selected from a group, consisting of dyslipidemia, hyperlipidemia, atherosclerosis, chronic heart failure, transient and permanent ischemic attack including cerebrovascular accident and stroke and peripheral arterial occlusive disease.
摘要翻译：琥珀酸γ-丁基甜菜碱及其药物组合物。新的药物组合物涉及预防和/或治疗选自由血脂异常，高脂血症，动脉粥样硬化，慢性心力衰竭，包括脑血管意外和中风和外周动脉闭塞性疾病在内的暂时性和永久性缺血性发作组成的组中的病症。

9. 发明申请

WO2010149653A1 A PHARMACEUTICAL COMPOSITION COMPRISING MELDONIUM SUCCINATE AND MEDICAL USES THEREOF 审中-公开
标题翻译：包含成ING ATE A A A OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF
公开(公告)号：WO2010149653A1
公开(公告)日：2010-12-29
申请号：PCT/EP2010/058816
申请日：2010-06-22
申请人： GRINDEKS, a joint stock company , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris , LEBEDEVS, Antons , MISNOVS, Anatolijs
IPC分类号： A61K31/194 , A61K31/197 , A61K33/06 , A61P3/06 , A61P9/00 , A61P9/04 , A61P9/10
CPC分类号： A61K31/194 , A61K31/195 , A61K33/06 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition with cardioprotective, antiischemic, antihypoxic and antioxidant properties for prevention and/or treatment of disorders, selected from the group of dyslipidemia, hyperlipidemia, atherosclerosis, coronary heart disease as chosen from the group of angina pectoris and myocardial infarction, chronic heart failure, transient and permanent ischemic attack including cerebrovascular accident and stroke and peripheral arterial occlusive disease, comprising Meldonium succinate alone or in the combination with inorganic succinate.
摘要翻译：一种具有心脏保护作用，抗缺血性，抗缺氧和抗氧化性质的药物组合物，用于预防和/或治疗选自心绞痛和心肌梗塞组的血脂异常，高脂血症，动脉粥样硬化，冠心病，慢性心力衰竭，包括脑血管意外和中风和外周动脉闭塞性疾病的暂时性和永久性缺血性发作，包括单独的琥珀酸米曲坦酯或与无机琥珀酸酯的组合。

10. 发明申请

WO2012158003A1 NOVEL FACTOR XII INHIBITOR 审中-公开
标题翻译：新的因素十二抑制剂
公开(公告)号：WO2012158003A1
公开(公告)日：2012-11-22
申请号：PCT/LV2012/000008
申请日：2012-05-16
申请人： TETRA, SIA , KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris
发明人： KALVINS, Ivars , BIRMANS, Anatolijs , VEVERIS, Maris
IPC分类号： A61K31/205 , A61K31/37 , A61P7/02
CPC分类号： A61K31/205 , A61K31/37 , A61K2300/00
摘要： The present invention provides meldonium acetylsalicylate as novel factor XII inhibitor and use thereof as anticoagulant agent. Further the present invention provides for synergistic therapeutic combination comprising meldonium acetylsalicylate and warfarin sodium for use as anticoagulant agent.
摘要翻译：本发明提供了乙酰水杨酸米曲坦作为新型因子XII抑制剂及其作为抗凝剂的用途。此外，本发明提供了包含乙酰水杨酸米曲坦和用于抗凝血剂的华法林钠的协同治疗组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式